/
ALKS
$52.94+$0.41 (+0.78%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.2B
167M shares
52-week range
$25.17 – $55.28
92% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$28.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.09B | $1.17B | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Cost of revenue | $176.4M | $180.4M | $178.3M | $197.3M | $218.1M | $253.0M | $245.3M | $196.5M |
| Gross profit | $917.9M | $990.6M | $860.4M | $976.4M | $893.7M | $1.41B | $1.31B | $1.28B |
| Gross margin | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% |
| R&D | $425.4M | $512.8M | $394.6M | $290.9M | $272.7M | $270.8M | $245.3M | $324.0M |
| Operating income | −$99.1M | −$175.5M | −$112.4M | $97.7M | −$6.1M | $414.1M | $420.6M | $254.0M |
| EBITDA | −$7.9M | −$103.0M | −$6.0M | $177.6M | $59.8M | $519.5M | $494.9M | $330.9M |
| Net income | −$139.3M | −$196.6M | −$110.9M | −$48.2M | −$158.3M | $355.8M | $367.1M | $241.7M |
| Net margin | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
| EPS (diluted) | -0.90 | -1.25 | -0.70 | -0.30 | -0.97 | 2.10 | 2.17 | 1.43 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.8B | $-0.40 | $-0.43–$-0.33 | 8 |
| 2027 | $1.9B | $0.56 | $-0.56–$2.43 | 7 |
| 2028 | $2.1B | $1.33 | $-0.85–$3.55 | 10 |
| 2029 | $2.4B | $2.35 | $2.27–$2.51 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$39.84
Price
$52.94
Implied downside
-25%
Peer comparison
Alkermes Inc. plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
www.alkermes.com- Employees
- 2,050
- IPO / List date
- Jul 16, 1991
- HQ
- DUBLIN 4, L2
Held by traders on TradeandTell
No one on the platform currently holds ALKS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALKS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALKS yet.
